As pathogenic variants in the gene for RBM20 appear with a frequency of 6% among Danish patients with dilated cardiomyopathy (DCM), it was the aim to investigate the associated disease expression in affected families.
D
ilated cardiomyopathy (DCM) is a condition characterized by unexplained dilation and impaired systolic function of the left ventricle (LV). 1 The most common presentation is with symptoms of heart failure (HF), whereas ventricular arrhythmias and sudden cardiac death (SCD) are less frequent as the initial manifestation of the disease. 1 The prognosis has improved considerably over the past decades because of better medical treatment, use of cardiac resynchronization therapy and application of implantable cardiac defibrillators (ICD). 2 However, DCM remains to be one of the most frequent causes of end-stage HF and heart transplantation (HTx). 3 The disorder has an estimated prevalence of 1:2500 and a familial appearance (>1 affected individual) in 30% to 50% of cases. [4] [5] [6] In the context of familial disease DCM is most often transmitted by autosomal dominant inheritance, and genetic investigations have reported pathogenic sequence variants in more than 100 different genes. 7 So far, disease-associated DNA-sequencevariants have most frequently been identified in the giant gene for Titin (TTN) encoding part of the cytoskeleton, sarcomeric protein genes, and the gene for lamin A/C which encodes a protein of the nuclear envelope. 7 Recently, the gene for RNA binding protein motif 20 (RBM20) was reported as the first DCM gene with regulatory properties that influences the posttranslational splicing of variety of genes including TTN. 8 So far, only few studies of RBM20 have reported about the relationship between genotype and phenotype. [8] [9] [10] [11] [12] The clinical information from these investigations has been limited by small numbers of individual patients (index-patients) or families with few affected relatives and a short period of follow-up. It was the aim of the study to substantiate our knowledge about the disease expression associated with pathogenic DNAsequence-variants in RBM20 by clinical investigations of a significant number of affected individuals followed for a considerable period of time.
METHODS
The data, analytic methods, and study materials will be made available on reasonable request to other researchers for purposes of reproducing the results or replicating the procedures.
Study Cohort
This investigation complied with the Declaration of Helsinki. It was approved by the local ethics committee (S-20140073) and the Danish data protection agency (14/17347). Informed consent was obtained from all participants.
Patients and relatives were included in the period from 2011 to 2017 at 3 tertiary referral University Hospitals of which one was also a transplant center. The catchment area of the hospitals included the geographic areas of Funen and Jutland which represented 54% (3 122 253/5 778 570 individuals) of the Danish population in 2017. 13 The study cohort consisted of unrelated index-patients with white ethnicity and a diagnosis of DCM who were shown to carry pathogenic DNA-sequence-variants in the gene for RBM20 after genetic investigations. Clinical data of the patients were collected retrospectively from their initial diagnosis of DCM until inclusion in the study and from then, prospectively until their most recent follow-up, their time of death or HTx.
In addition, their relatives at risk of disease development, who accepted the offer of predictive genetic testing and were shown to carry the pathogenic DNA-sequence variant within RBM20 of the index-patient, were also included in the study.
Information about family members who died before the current investigation was obtained retrospectively by reviewing available hospital notes and autopsy reports.
Information from each individual participating in the study was collected at multiple time points and included: (1) symptoms of cardiac disease, (2) results of ECG-and Holterrecordings, (3) results of echocardiography, (4) implantation of pacemaker or defibrillator, (5) disease complications including ventricular arrhythmias, HTx, and (6) all-cause mortality.
Control Cohort
The control cohort consisted of patients with familial DCM defined as the presence of >1 affected individual after clinical investigations of relatives at risk of having inherited
WHAT IS NEW?
• This study represents the most comprehensive investigation to date of the disease expression in 80 carriers of pathogenic DNA-sequence variants in the gene for RBM20.
• Sixty percent of all male RBM20-carriers experienced a major cardiovascular event before the age of 40 years, while this happened in <5% of females.
• Only male carriers developed end-stage heart failure requiring cardiac transplantation.
• Pathogenic RBM20-variants were associated with a severe disease expression which appeared to be sex specific, because males had a significantly shorter event-free survival rate than female carriers
WHAT ARE THE CLINICAL IMPLICATIONS?
• The severe disease expression in carriers of pathogenic RBM20-variants, suggested that close clinical follow-up of affected as well as unaffected individuals is warranted to ensure adequate and timely treatment.
• Primary prophylactic implantable cardiac defibrillator treatment may be considered in carriers of pathogenic RBM20-variants once they develop dilated cardiomyopathy because one third of the affected individuals either died suddenly or experienced episodes of ventricular fibrillation/sustained ventricular tachycardia.
the condition. Furthermore, genetic investigations of ≥76 recognized and likely DCM-genes (see below) had been unable to identify any pathogenic or likely pathogenic DNA-sequence variants. This cohort of patients fulfilled the same diagnostic criteria as the study cohort and was included at the same time and location as carriers of pathogenic RBM20-variants. 14 DCM was diagnosed in accordance with generally accepted criteria when echocardiography identified unexplained left ventricle dilation, and impaired contractile performance with a LVEDd >112% predicted for age and body surface area and a LVEF ≤45%.
Echocardiography and Diagnostic Criteria

1
Coronary disease was excluded in index-patients >35 years of age at diagnosis by the use of coronary angiography or cardiac computed tomography. 15 In addition, patients who were pregnant or had hypertension, a history of alcohol abuse, heart valve disease, congenital heart disease, autoimmune, endocrine, metabolic, or neuromuscular disease known to be associated with HF were not included in the study.
RBM20-carriers who experienced SCD <50 years of age were also considered to have DCM.
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Sudden Cardiac Death
SCD was defined in accordance with generally accepted criteria as a sudden and natural unexpected death. In unwitnessed cases, SCD was defined as the cause of death in a person last seen alive and functioning normally 24 hours before dying and in witnessed cases as an acute change in cardiovascular status within 1 hour of the time to death. 16 
Ventricular Arrhythmia
Ventricular arrhythmia (VA) was defined as documented episodes of (1) sustained ventricular tachycardia lasting >30 seconds requiring cardioversion, (2) ventricular fibrillation, or (3) SCD.
Genetic Investigations
All index-patients in both the study and control cohort underwent genetic investigations by the use of Illumina Hiseq NGS technology. Three different laboratories were used which all fulfilled the requirements for clinical diagnostic testing according to the UNE-EN ISO 15189 quality standard. [17] [18] [19] The number of genes investigated varied from 76 to 242 and depended solely on the diagnostic gene panels provided by the individual laboratory ( Table I in the Data  Supplement) .
Once a pathogenic DNA-sequence-variant was identified in the index-patient, relatives were offered predictive testing by use of Sanger Sequencing of the specific variant.
Filtering and Classification of DNASequence Variants
Sequence variants were filtered and classified according to the consensus recommendations from the American College of Medical Genetics and Genomics and the Association for Molecular Pathology as pathogenic, likely pathogenic (LP), variant of unknown significance (VUS), benign or likely benign. 20 The initial raw filtering and classification was obtained by use of the software Ingenuity Variant Analysis (Qiagen) and Intervar (Wang Genomics Lab). [21] [22] [23] Subsequently, all pathogenic/likely pathogenic variants as well as VUS were reassessed individually and reclassified according to American College of Medical Genetics and Genomics criteria, after cosegregation analysis, literature-and database review. [24] [25] [26] [27] [28] RBM20-variants identified within the Arginine-Serine rich domain of exon 9 were considered to fulfill the hotspot American College of Medical Genetics and Genomics criteria (PM1) since previous investigations have reported identical pathogenic variants in the same domain and no benign variants have been reported so far. Evidence of segregation was considered as strong when appearing in ≥7 affected individuals, moderate when appearing in ≥5, and supporting when appearing in ≥3.
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Variants classified as pathogenic according to American College of Medical Genetics and Genomics were considered to be disease associated and suitable for genetic testing when they:
1. Appeared in ≥7 individuals fulfilling DCM diagnostic criteria based on the findings in the current study and previous reports.
24 -27,30 2. Occurred with an allele frequency <1:10 000 in the Genome Aggregation Database.
28,31
Haplotype Analysis
To investigate if common founders of families carrying identical pathogenic RBM20-variants were present, haplotype analyses were made by the use of Sanger sequencing of 3 single nucleotide polymorphisms in the 3-prime-untranslated-region (3-UTR) of RBM20 (genomic positions, 112596184/c.*448C>T; 112596570/c.*834G>T; and 112598602/c.*2866C>T). All single nucleotide polymorphisms were localized within a distance of <27 000 nucleotides from the pathogenic RBM20-variant. On average 3 carriers of the pathogenic variant and 1 noncarrier from each family were selected for haplotype analysis. The primers used for haplotype analysis are available on request.
Statistics
Continuous variables were reported as mean±SD for normally distributed data or otherwise as median and interquartile range. (Bonferroni). The follow-up period in survival analyses lasted from the date of birth until the first episode of VA, HTx, death from HF (composite end point) or the date of the most recent follow-up (censoring). Event rates were estimated using the Kaplan-Meier method and compared using the log-rank test. Furthermore, univariate cox proportional hazard regression was used to calculate hazard ratios) and 95% CI. Family structure was taken into account by estimating robust clustered standard errors. P-values <0.05 were considered to be statistically significant. Statistical analyses were performed by the use of software from STATA (version 15).
RESULTS
Genetic Investigations
Initially, clinical and genetic investigations of ≥76 potential DCM related genes were performed in 111 DCMindex patients including 436 of their relatives at risk of having inherited the condition. 32 Familial DCM occurred in 34% (38/111) of cases. A total of 14 different pathogenic DNA-sequence variants suitable for genetic testing were identified in 19 apparently unrelated indexpatients (17%) with a frequency of 45% (17/38) in familial DCM and 3% (2/73) in sporadic DCM. The frequency of pathogenic RBM20-variants in this cohort of patients was 6% (7/111) and appeared in familial DCM only. Following these results, genetic investigations were routinely offered to all consecutive index-patients with familial DCM, and an additional 8 RBM20 families were identified and included in this study.
The genetic investigations identified 5 different recognized pathogenic RBM20-variants suitable for genetic testing in 15 families with a total of 80 carriers ( Figure 1 and Table 1 : p.Arg634Gln, p.Arg636His, p.Arg636Ser, p.Pro638Leu, and p.Glu913Lys). 6, [8] [9] [10] [11] [12] Ten index-patients were shown to carry the same p.Arg636Ser amino acid substitution. Seven of these families were available for haplotype analyses which revealed cosegregation between 3 intragenic single nucleotide polymorphisms of RBM20 and p.Arg636Ser. These findings suggested a common disease allele and, thereby, a common founder of the pathogenic variant.
In family B the index-patient and 1 affected relative carried the recognized disease-associated pathogenic RBM20-variant p.Arg636Ser as well as a VUS within the DCM gene for BAG3 (p.Arg71Trp) which appeared with a frequency of 1:7070 in the Genome Aggregation Database (Table 1) . 33 An additional 4 index patients were shown to carry 4 different VUS of RBM20 (Table 1 : p.Met196Val, p.Arg392Trp, p.Asp674Gly, and p.Pro1039Ser). Three of these index-patients also carried a pathogenic truncating TTN variant or a VUS in recognized DCM genes for either ACTC1 or TNNI3 (Table 1 and Figure I in the Data Supplement). [34] [35] [36] Unfortunately, the number of affected individuals in these families was too small to draw conclusions about the potential pathogenicity of these sequence variants and, therefore, they were excluded from the analyses in this study.
Clinical Investigations of RBM20-Carriers
Age at Diagnosis and Symptoms Clinical investigations of 80 individuals carrying pathogenic RBM20-variants within 15 families identified a total of 53 affected individuals including index-patients, which resulted in a penetrance of 66% (53/80). They were followed for a median period of 86 months (24-150 months) from their first clinical evaluation and were diagnosed with DCM at their initial investigation (n=49) or developed the condition during follow-up (n=4). The mean age at diagnosis of index-patients and affected relatives was 40±15 and 35±15 years, respectively. Most affected individuals were diagnosed between 30 and 39 years of age ( Figure 2 and Table 2 ). Twentyseven individuals (34%) had a normal phenotype at their most recent follow-up at a mean age of 38±17 years (males: 37±17 years and females: 40±17 years) (Figures 1 through 3 and Table 2 ).
The total number of relatives carrying pathogenic RBM20-variants without symptoms of cardiac disease was 44 of which 17 (39%) were diagnosed with DCM following clinical family screening (Figure 3 ). These asymptomatic individuals with DCM were identified at a significantly younger age compared with 16 symptomatic relatives who were diagnosed with DCM because of cardiac symptoms before family screening was initiated (29±12 versus 43±16 years; P=0.02; Table II in the Data Supplement).
An additional 5 relatives who were obligate carriers of pathogenic RBM20-variants died suddenly as the initial symptom of disease at an average age of 35±6 (Figure 1 ; Family D, III.4 and III.6; Family F, II.2 and II.3; and Family H, II.1). They all underwent autopsy and received a postmortem diagnosis of DCM. According to the autopsy report of individual FII.3 her heart was enlarged with a dilated LV and a weight of 475 g (0.8% of her body weight). The histology was characterized by myocyte hypertrophy and fibrosis. Unfortunately, details of the autopsies in the remaining 4 SCDs were unavailable except for the main conclusion.
Echocardiography
Echocardiography of all carriers of pathogenic RBM20-variants with DCM at initial diagnosis revealed a mean LVEDd and LVEF of 65±9 mm and 32±12%, respectively (Table 3) . Asymptomatic individuals who fulfilled DCM diagnostic criteria and identified by clinical investigations of relatives had a significantly better LVEF than relatives who had been referred because of symptoms (LVEF, 38±8% versus 27±12%; P=0.03; Table II in the Data Supplement). There was no significant change in LVEF (32±12% versus 32±13%; P=0.76) or LVEDd (66±10% versus 68±10% mm; P=0.11) of RBM20-carriers with DCM after an average period of 7 years of follow-up.
Arrhythmias
Two individuals had supra VAs at diagnosis, while 10 developed atrial fibrillation during follow-up. One individual developed a sick sinus node syndrome at the age of 51. Five individuals developed left bundle branch block. No one was diagnosed with advanced atrioventricular conduction disease.
Three individuals were successfully resuscitated from a cardiac arrest because of ventricular fibrillation whereas 2 individuals had episodes of sustained ventricular tachycardia requiring cardioversion. Five of 16 patients treated with a primary prophylactic ICD received appropriate shock at a mean age of 40±6 years and a median follow-up period of 5 years. Two of these individuals underwent HTx at a later stage. One individual who had been followed for 8 years with a LVEF of 30%, died suddenly at the age of 33. An additional, 5 individuals also died from SCD as mentioned above. Most affected individuals experienced their first episode of VA between 30 and 39 years of age (Figure 2) .
In total, 16 of the 53 individuals with DCM (30%) experienced at least one episode of severe VA. There was no significant difference in LVEF at diagnosis among patients with episodes of VAs compared with DCM patients without VAs (28±13% versus 34±12%; P=0. 19) , whereas the mean LVEF preceding an episode of sustained ventricular tachycardia or ventricular fibrillation was 30±12% (median 30%; range, 10%-47%). However, 36% (4/11) of the patients with DCM who experienced a VA had a LVEF >30%. There was no difference in HF therapy with angiotensin-converting enzyme-inhibitors and β-blockers between patients with and without VAs (P=0.69 and P=0.13, respectively).
RBM20-carriers with a normal echocardiography did not have symptoms or documented episodes of VAs by Holter-recordings.
Sex-Specific Disease Expression
Eleven males from 8 different families and no females underwent HTx because of end-stage HF (P<0.01) at a mean age of 33±16 years (Table 3 ). Four teenagers from 3 different families received a transplant at the age of 13 (II.2, family R), 14 (III.2, family G), 17 (III.5, family H), and 18 (III.7, family H; Figure 1 ).
Males were diagnosed at a significantly younger age than females (29±11 versus 48±12 years, P<0.001). They also had a lower LVEF at diagnosis (29±13% versus 38±8%; P<0.009), whereas the difference in LVEDd at diagnosis was nonsignificant when indexed for body surface area (Table 3 ). Males were significantly younger when experiencing their first episode of VA (37±5 versus 54±16 years; P=0.006). By the age of 40 years, 60% males had either received a cardiac transplant or experienced VA, whereas this happened in <5% of females ( Figure 4A ). However, there was no significant sex-specific difference in the number of VA episodes (Table 3) . Affected males also died or experienced a disease complication significantly earlier in life than affected females (log-rank, P<0.001; hazard ratios 24.05; 95% CI, 2.98-196.21; P=0.003; Figure 4A ). There were no significant differences in the number individuals who were identified by family screening, their New York Heart Association class, pharmacological HF treatment, or the frequency of ICD implantations between sexes (Table 3) .
Adjusting for family structure did not change the significance levels in the statistical analyses (data not shown).
Disease Expression Among Affected Relatives
Affected relatives who were asymptomatic at diagnosis were diagnosed with DCM at a younger age, had a higher LVEF at diagnosis (38±8% versus 27±12%; P=0.03), and fewer episodes of VAs during followup (6% versus 52%; P=0.008) than affected relatives who were symptomatic at diagnosis (Table I in the Data Supplement). Two of the asymptomatic relatives at diagnosis deteriorated rapidly during follow-up and underwent HTx at the age of 17 and 19 years, respectively (Table II in the Data Supplement). There were no significant differences between index-patients and their affected relatives regarding pharmacological HF treatment, frequency of ICD implantations, VAs, and HTx during follow-up (Table II in the Data Supplement).
Comparison of the Disease Expression Among DCM Patients Carrying Pathogenic RBM20-Variants and Patients Having Familial DCM of Unknown Genetic Cause
The disease expression among carriers of pathogenic RBM20-variants and patients with familial disease in whom the genetic investigations failed to identify any pathogenic or likely pathogenic variants was compared. Male patients (n=31) with DCM carrying pathogenic RBM20-variants were significantly younger at diagnosis (29±11 versus 49±16 years; P<0.001) than males (n=30) with familial DCM of unknown genetic etiology (Table 4 ). In addition, they had a significantly shorter event-free survival than males with familial DCM of unknown genetic cause (log-rank; P=0.001; hazard ratios 3.47; 95% CI, 1.58-7.60; P=0.002; Figure 4B ). There were no further differences in the clinical characteristic, pharmacological HF treatment or frequency of ICD implantations between males in the two groups.
Female patients (n=22) with DCM carrying pathogenic RBM20-variants were significantly older at diagnosis than females (n=14) with familial DCM of unknown genetic cause (48±12 versus 33±16 years; P=0.003). There were no further significant differences in clinical characteristics, pharmacological HF treatment, frequency of ICD implantations or event-free survival between females in the 2 groups (log-rank, P=0.19; hazard ratios 0.46; 95% CI, 0.14-1.51; P=0.20; Table III and Figure II in the Data Supplement).
DISCUSSION Genetic Investigations and Penetrance
Five recognized pathogenic RBM20-variants were identified of which the p.Arg636Ser amino acid substitution appeared in more than two thirds of all RBM20-carriers. 6, [8] [9] [10] [11] [12] Haplotype analyses using 3 single nucleotide polymorphisms localized in close proximity to the pathogenic RBM20-variant suggested that this variant was likely to have originated from a common founder.
A number of rare sequence variants were identified in RBM20 as well as in additional recognized DCM genes. Although they were absent in controls the number of affected carriers of these variants were too small to determine their possible impact on disease expression and, therefore, they were considered unsuitable for genetic testing. Future studies may help to determine the impact of these variants and also clarify if DCM in the context of RBM20-disease may be explained by di-genic inheritance because of the appearance of variants in >1 recognized DCM gene as seen in 4 index patients of this study (Table 1 and The penetrance of DCM among carriers of pathogenic RBM20-variants was 66% including index patients and depended on age and sex with males being diagnosed at a significantly younger age than females. Remarkably, 7 young males and no females developed DCM in their teens, necessitating HTx in 4 individuals before the age of 19.
Clinical Investigations and Disease Expression
The disease expression was severe; one third of affected carriers died suddenly or experienced at least 1 Figure 3 . Distribution of carriers of pathogenic RBM20-variants identified because of symptoms or by clinical family screening. An additional 4 index-patients were shown to carry VUS within RBM20 and did not take part in any of the analyses in the study. DCM indicates dilated cardiomyapathy; SCD, sudden cardiac death; and VUS, variant of unknown significance. (10) 20±12 (11) 43±14 (13) 37±5 (4) 41±18 (18) 43 (1) 99 , (34) p.Pro638Leu
p.Glu913Lys 1/9 8/9 (88) 36 (1) 24±12 (5) 71 (1) 28 (1) 28 (1) 27±15 (3) 37 . (7) Total 15/80 53/80 (66) 40±15 (15) 29±12 (17) 43±16 (16) 35±6 (5) 38±17 (27) 31±15 (4) 86 , (48) DCM indicates dilated cardiomyopathy; IQR, interquartile range (25%-75%); and SCD, sudden cardiac death. *Follow-up data were available in 48 individuals since 5 individuals had died suddenly as the initial manifestation of disease.
episode of ventricular fibrillation/sustained ventricular tachycardia during 7 years of follow-up. In addition, 21% received a cardiac transplant. Again, the disease expression was significantly worse among males in whom 60% experienced a major cardiac event before the age of 40 years, whereas this occurred in <5% of females ( Figure 4A ). It was evident that male DCM patients carrying pathogenic RBM20-variants had a significantly shorter event-free survival than males with familial DCM of unknown genetic cause ( Figure 4B ). Furthermore, female RBM20-carriers were older at diagnosis than both females with familial DCM of unknown genetic cause and male RBM20-carriers.
This sex-specific disease expression may be explained by yet unidentified modifying genetic variants, which may protect female carriers from adverse events in addition to differences in lifestyle, hormonal status, and overall genetic constitution. In this context, it is of interest that a similar sex-specific disease expression has been reported to be associated with pathogenic variants in the gene for lamin A/C, in which males appeared to have more episodes of malignant VAs and a higher frequency of end-stage HF than females. 37 The fact that males had a lower LVEF at diagnosis than females may well explain the high frequency of HTx and SCD among male RBM20-carriers. Furthermore, the absence of VA and symptoms of disease in RBM20-carriers with a normal cardiac investigation also suggested that VA were related to impaired LV function. However, VAs also appeared in 4 individuals with a LVEF between 30% to 47%, suggesting that other factors than impaired LV function may be associated with VAs. Interestingly, the results of a recent investigation of a RBM20 knock-out mouse model showed that loss of the protein for RBM20 disturbed Ca 2+ handling and lead to a more proarrhythmic Ca 2+ release from the sarcoplasmic reticulum which may explain the high frequency of VAs. 38 To substantiate these findings, additional experimental studies of genetically modified animal models expressing pathogenic missense variants identified in humans would be required to provide a basis for future pharmacological intervention studies. A, Event-free survival of males and females with DCM carrying pathogenic RBM20-variants. Events were defined as death from end-stage heart failure, cardiac transplantation, sudden cardiac death, and first episode of ventricular fibrillation or sustained ventricular tachycardia. Hatch-mark indicates age at most recent follow-up. B, Event-free survival of males with DCM carrying pathogenic RBM20-variants and males with familial DCM of unknown genetic cause. Events were defined as death from end-stage heart failure, cardiac transplantation, sudden cardiac death, and first episode of ventricular fibrillation or sustained ventricular tachycardia. Hatch-mark indicates age at most recent follow-up.
Clinical Implications
Based on the findings in this and previous studies pathogenic variants within RBM20 appeared to be associated with an adverse prognosis in both indexpatients and their relatives. The finding of DCM in 39% of otherwise asymptomatic RBM20-carriers illustrated the importance of family screening. These individuals were identified 14 years earlier than relatives who had been diagnosed with DCM because of symptoms of HF. The diagnosis of asymptomatic individuals with DCM allowed initiation of presymptomatic anticongestive medical therapy which may hopefully postpone the development of severe LV dysfunction, VA, and the need for HTx.
Close clinical surveillance of RBM20-carriers from the age of 10 appeared important because several individuals developed end-stage HF in their teens whereas few carriers experienced adverse complications beyond the age of 70 years.
Limitations
The study was conducted at 3 tertiary referral University Hospitals of which 1 was also a transplant center, which may have introduce referral bias towards more severely affected individuals.
Haplotype analyses suggested that the most frequent pathogenic RBM20-variant (p.Arg636Ser) in the cohort was likely to have arisen from a common ancestor. This may have represented a potential confounder towards a more uniform disease expression among carriers because of a common genetic background. However, the disease expression associated with the p.Arg636Ser variant observed in this study appeared to be the same as reported previously which favored an effect of the pathogenic RBM20-variant by itself more than a potential effect of common ancestry. 8 The fact that males with familial DCM of unknown genetic cause were significantly older at diagnosis compared males with DCM carrying pathogenic RBM20-variants may have introduced a confounder because the development of their condition may have been influenced by a longer exposure to environmental and lifestyle risk for developing DCM.
CONCLUSIONS
Pathogenic RBM20-variants appeared to be associated with a severe disease expression and an early onset, especially in males. These findings suggested that clinical and genetic investigations are important to identify patients at high risk of developing disease complications to initiate adequate and timely treatment.
